Henry Moore, MD
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (36.0%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Ipsen Biopharmaceuticals, Inc at 29.9% of the total. 2025 is the largest year on record at $10,540, 2.7 times the $3,928 reported in 2019. Among neurology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 159 payments — averaging $245.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ipsen Biopharmaceuticals, Inc$12K
- AbbVie$9K
- Teva Pharmaceuticals USA, Inc.$4K
- Amneal Pharmaceuticals LLC$4K
- Medtronic$2K
- Acadia Pharmaceuticals Inc$2K
- plus $6K from 19 others
Across 293 payments — averaging $3603.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sage Therapeutics, LLC$524K
- Amneal Pharmaceuticals LLC$210K
- Neurocrine Biosciences, Inc.$172K
- Sunovion Pharmaceuticals Inc.$112K
- Teva Pharmaceuticals USA, Inc.$31K
- Acadia Pharmaceuticals Inc$8K
What the payments were for
- Consulting fees$14,04636%
- Speaking & faculty fees$12,25731%
- Travel & lodging$4,34411%
- Food & beverage$8,22721%
- Education$1720%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ipsen Biopharmaceuticals, Inc | 6 | $11,659 |
| AbbVie(2 entities) | 26 | $8,920 |
| Teva Pharmaceuticals USA, Inc. | 11 | $4,010 |
| Amneal Pharmaceuticals LLC | 15 | $3,777 |
| Medtronic(2 entities) | 21 | $2,303 |
| Acadia Pharmaceuticals Inc | 13 | $1,887 |
| Lundbeck LLC | 3 | $1,886 |
| Sage Therapeutics, LLC | 16 | $1,670 |
| Neurocrine Biosciences, Inc. | 12 | $871 |
| Abbott | 4 | $396 |
| Merz Pharmaceuticals, LLC | 8 | $369 |
| Kyowa Kirin, Inc. | 4 | $284 |
| UCB, Inc. | 3 | $147 |
| MDD US Operations, LLC | 2 | $140 |
| Adamas Pharmaceuticals, Inc. | 2 | $129 |
| Supernus Pharmaceuticals, Inc. | 2 | $126 |
| Boston Scientific | 2 | $121 |
| Genentech, Inc. | 1 | $91 |
| Biogen | 2 | $86 |
| Revance Therapeutics, Inc. | 1 | $75 |
| Amgen | 1 | $26 |
| Azurity Pharmaceuticals, Inc. | 1 | $24 |
| Vertical Pharmaceuticals, LLC | 1 | $17 |
| Acorda Therapeutics, Inc | 1 | $17 |
| Lilly USA, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$39,046 in reported general payments places this provider in the 90th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 70 | $566,784 |
| NuplazidPimavanserin Tartrate | 103 | $554,858 |
| GocovriAmantadine Hcl | 33 | $173,425 |
| RytaryCarbidopa/Levodopa | 107 | $152,314 |
| AustedoDeutetrabenazine | 28 | $149,166 |
| Austedo XrDeutetrabenazine | 15 | $72,225 |
| InbrijaLevodopa | 18 | $52,630 |
| NeuproRotigotine | 24 | $32,522 |
| OngentysOpicapone | 21 | $21,640 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 596 | $19,515 |
| NuedextaDextromethorphan Hbr/Quinidine | 11 | $17,036 |
| Entacapone | 44 | $12,997 |
| Rasagiline Mesylate | 66 | $12,179 |
| CrexontCarbidopa/Levodopa | 15 | $11,938 |
| Rivastigmine | 39 | $8,805 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza, Ongentys | $871 | $588,42591 claims |
| Acadia Pharmaceuticals IncNuplazid | $1,887 | $554,858103 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $4,010 | $221,39143 claims |
| MDD US Operations, LLCGocovri | $140 | $173,42533 claims |
| Amneal Pharmaceuticals LLCRytary, Crexont | $3,777 | $164,252122 claims |
| Acorda Therapeutics, IncInbrija | $17 | $52,63018 claims |
| UCB, Inc.Neupro | $147 | $32,52224 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,434 neurology providers in Florida.
Other neurology in Miami
- Diego Torres-RussottoMiami$652K
- Bruno GalloMiami$313K
- Brad HerskowitzMiami$273K
- Flavia NelsonMiami$264K
- Corneliu LucaMiami$257K
- Kottil RammohanMiami$176K
- Stuart IsaacsonBoca Raton$3.9M
- Selim BenbadisTampa$2.1M
- Derrick RobertsonTampa$1.8M
- Robert HauserTampa$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.